# Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors

> **NCT04886271** · PHASE2 · COMPLETED · sponsor: **Hangzhou Hanx Biopharmaceuticals, Ltd.** · enrollment: 20 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** HX009

## Key facts

- **NCT ID:** NCT04886271
- **Lead sponsor:** Hangzhou Hanx Biopharmaceuticals, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-12
- **Primary completion:** 2024-01-12
- **Final completion:** 2024-02-22
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04886271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04886271, "Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04886271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*